Fulgent Genetics Price to Sales Ratio 2015-2024 | FLGT
Historical PS ratio values for Fulgent Genetics (FLGT) over the last 10 years. The current P/S ratio for Fulgent Genetics as of November 12, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Fulgent Genetics P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2024-11-12 | 19.16 | 1.97 | |
| 2024-06-30 | 19.62 | $9.71 | 2.02 |
| 2024-03-31 | 21.70 | $9.63 | 2.25 |
| 2023-12-31 | 28.91 | $9.71 | 2.98 |
| 2023-09-30 | 26.74 | $9.52 | 2.81 |
| 2023-06-30 | 37.03 | $10.13 | 3.66 |
| 2023-03-31 | 31.22 | $11.87 | 2.63 |
| 2022-12-31 | 29.78 | $19.88 | 1.50 |
| 2022-09-30 | 38.12 | $25.82 | 1.48 |
| 2022-06-30 | 54.53 | $29.71 | 1.84 |
| 2022-03-31 | 62.41 | $30.67 | 2.03 |
| 2021-12-31 | 100.59 | $32.10 | 3.13 |
| 2021-09-30 | 89.95 | $36.24 | 2.48 |
| 2021-06-30 | 92.23 | $33.25 | 2.77 |
| 2021-03-31 | 96.62 | $29.02 | 3.33 |
| 2020-12-31 | 52.10 | $17.70 | 2.94 |
| 2020-09-30 | 40.04 | $5.88 | 6.81 |
| 2020-06-30 | 16.00 | $2.09 | 7.64 |
| 2020-03-31 | 10.76 | $1.78 | 6.04 |
| 2019-12-31 | 12.90 | $1.72 | 7.51 |
| 2019-09-30 | 10.39 | $1.58 | 6.56 |
| 2019-06-30 | 6.68 | $1.37 | 4.89 |
| 2019-03-31 | 5.95 | $1.22 | 4.86 |
| 2018-12-31 | 3.17 | $1.19 | 2.66 |
| 2018-09-30 | 3.93 | $1.12 | 3.52 |
| 2018-06-30 | 4.14 | $1.06 | 3.92 |
| 2018-03-31 | 4.00 | $1.02 | 3.93 |
| 2017-12-31 | 4.38 | $1.05 | 4.18 |
| 2017-09-30 | 4.79 | $1.23 | 3.88 |
| 2017-06-30 | 6.39 | $1.37 | 4.66 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.586B | $0.289B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tempus AI (TEM) | United States | $10.500B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $5.733B | 148.28 |
| Inspire Medical Systems (INSP) | United States | $5.716B | 178.27 |
| Axonics (AXNX) | United States | $3.603B | 1762.25 |
| IRhythm Technologies (IRTC) | United States | $2.729B | 0.00 |
| Privia Health (PRVA) | United States | $2.710B | 225.80 |
| Enovis (ENOV) | United States | $2.621B | 17.77 |
| Omnicell (OMCL) | United States | $2.264B | 74.08 |
| Azenta (AZTA) | United States | $2.250B | 112.17 |
| 10x Genomics (TXG) | United States | $1.898B | 0.00 |
| Schrodinger (SDGR) | United States | $1.620B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.617B | 0.00 |
| Phreesia (PHR) | United States | $1.235B | 0.00 |
| Standard BioTools (LAB) | United States | $0.763B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.571B | 0.00 |
| Talkspace (TALK) | United States | $0.569B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.528B | 91.40 |
| Health Catalyst (HCAT) | United States | $0.495B | 0.00 |
| Pulmonx (LUNG) | United States | $0.278B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.261B | 0.00 |
| TruBridge (TBRG) | United States | $0.234B | 67.96 |
| P3 Health Partners (PIII) | United States | $0.140B | 0.00 |
| American Well (AMWL) | United States | $0.136B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.098B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.065B | 0.00 |
| HeartBeam (BEAT) | United States | $0.063B | 0.00 |
| 111 (YI) | China | $0.056B | 0.00 |
| CareCloud (CCLD) | United States | $0.051B | 0.00 |
| Zepp Health (ZEPP) | China | $0.049B | 0.00 |
| Outset Medical (OM) | United States | $0.045B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.041B | 0.00 |
| Movano (MOVE) | United States | $0.028B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.023B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.017B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.013B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.011B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.009B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.007B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.005B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Zhongchao (ZCMD) | China | $0.002B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |